ClinicalTrials.gg
RecruitingNCT05851326Updated Apr 23, 2026

Low-Energy Ultrasound, Electrical and Magnetic Field Stimulation in Therapy-Resistant Myofascial Pain Syndrome

An interventional study of Active Sonodyn and Sham in Myofascial Pain Syndrome - Lower Back, Myofascial Pain Syndrome - Neck and Myofascial Pain Syndrome - Tension Headache, sponsored by Sobet AG. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Sobet AG · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

Sonodyn is an investigational device that within this clinical investigation is intended for use in patients suffering from low back pain, tension headache or neck pain, originating from therapy-resistant myofascial pain syndrome.

Myofascial pain syndrome is a prevalent pain condition in the adult population and a common cause of pain and dysfunction in the musculoskeletal system. It is a trigger point-induced regional musculoskeletal pain disorder affecting one or more muscles or groups of muscles.

Sonodyn is a handheld medical device that combines low-energy ultrasound, electrical and magnetic field stimulation for non-invasive transcutaneous treatment of chronic myofascial pain syndrome. Sonodyn is a battery-operated, rechargeable stimulation device to be placed over specific trigger points for associated pain patterns in the human body. It emits ultrasound, electrical and magnetic stimulation signals with a pre-defined set of parameters for each of the independently operated power sources.

The study will follow a prospective, randomized, sham-controlled, double-blind parallel group design. It will be conducted as a multi-center investigation at 6 sites in Austria and Switzerland. Patients are randomized in a 2:1 ratio into Treatment and Control.

  • Active Sonodyn therapy (Treatment)
  • No therapy (Sham Control)

Two types of Sonodyn devices will be used: a fully functional one for Therapy arm patients that can deliver stimulation, and a non-functional one for Control arm patients that cannot convey any energy signals to the device output. The devices will look fully identical.

Randomization will be stratified by study site, pain diagnosis and sex of the patient.

For each subject, after a screening phase of 1 week, patients will be treated for 3 weeks with a follow-up of additional 8 weeks, adding up to 12 weeks. During treatment patients will activate their device 3 times a day for 10 minutes each.

During screening, treatment and follow-up period, all patients will twice per day report the average and maximum intensity of their pain Numeric Rating Scale (NRS). Patients will also enter the date, amount, and time of intake of rescue medication, if applicable.

The primary objective of this study is to assess the impact on pain. Secondary objectives are to compare the performance between active therapy and sham, as well as to correlate changes in pain intensity with other pain related scales.

02

Conditions studied

  • Myofascial Pain Syndrome - Lower Back
  • Myofascial Pain Syndrome - Neck
  • Myofascial Pain Syndrome - Tension Headache

Keywords

  • Myofascial Pain Syndrome
  • Low-Energy Stimulation
  • Ultrasound, Electrical and Magnetic Field Stimulation
  • Transcutaneous Pain Therapy
  • Chronic Pain
03

In context

Myofascial Pain Syndromes

340 studies on the registry are indexed under Myofascial Pain Syndromes; 67 are open to participants now.

This study's planned enrollment of 126 is above the median of 51 across 308 interventional studies indexed under Myofascial Pain Syndromes.

Browse Myofascial Pain Syndromes studies →

Lead sponsor

This is the only study on the registry with Sobet AG as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 to 99 years at screening
  • Patient has an understanding of the study and its procedures, agrees to its provisions, and gives written prior to any study-related procedures
  • Patient is suffering from one of the following chronic pain conditions originating from myofascial pain:

    • low back pain
    • tension headache
    • neck pain

having been persisting for a minimum of 3 months and where myofascial pain syndrome is the pre-dominant cause for pain.

  • Patient is constant with respect to pain treatment for 1 week during the screening phase
  • A daily average NRS >= 4 on 4 out of 7 days in the screening phase
  • Compliance with the daily status reporting requirements as demonstrated

Exclusion criteria

Exclusion Criteria:

  • Patients with active implants
  • Allergy against rescue medication used during the study
  • Pregnancy
  • Mental or physical impairments that represent a source of risk for handling the device
  • Patients with cerebral spams (epilepsy)
  • Patients with psychiatric diseases or somatoform pain disorders
  • Patients with oral morphine equivalent of more than 120mg daily dose
  • Patients taking centrally acting muscle relaxants like Sirdalud or benzodiacepines
  • Patients with a against NSAID's
  • Presence of artificial joints made from methylmethacrylate or polyethylene at stimulation site
  • Presence of ferromagnetic metal implants at stimulation site, especially aneurysm clips, dental implants, etc.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    Active Sonodyn Therapy (Treatment Group)

    Patients will remain on treatment for 3 weeks and will activate their device 3 times a day for 10 minutes each.

    Device: Active Sonodyn

  • Sham comparator
    Sham Therapy (Control Group)

    Patients will remain on sham treatment for 3 weeks and will activate their device 3 times a day for 10 minutes each.

    Device: Sham

Interventions

  • DeviceActive Sonodyn

    Sonodyn emits ultrasound, electrical and magnetic stimulation signals with a pre-defined, fixed set of parameters for each of the independently operated power sources.

  • DeviceSham

    Non-functional Sonodyn device that cannot convey any energy signals to the device output, however, looks and behaves fully identical as the active Sonodyn device.

06

What researchers measure

Primary outcomes

  1. Average Numeric Rating Scale (NRS)

    Change in Treatment group from Baseline to EoT in average Numeric Rating Scale (NRS, 0-10, with 0 indicating no pain and 10 indicating the worst pain that the patient had ever experienced) per day

    Time frame: 3 weeks

Secondary outcomes

  1. Difference in average NRS between groups - Baseline to EoT

    Difference between groups in change of average NRS from Baseline to EoT

    Time frame: 3 weeks

  2. Maximum NRS - Baseline to EoT

    Change from Baseline to EoT in maximum NRS in both groups

    Time frame: 3 weeks

  3. Average and maximum NRS - Baseline to end of follow-up

    Change from Baseline to end of follow-up in average and maximum NRS in both groups

    Time frame: 11 weeks

  4. AUC of average and maximum NRS - Baseline to EoT

    Baseline-adjusted area under the curve (AUC) of average and maximum NRS from Baseline to EoT in both groups

    Time frame: 3 weeks

  5. Average and maximum NRS - Follow-up

    Average and maximum NRS during follow-up in both groups

    Time frame: 8 weeks

  6. Medication consumption

    Pain and rescue medication consumption during treatment and follow-up phase in both groups

    Time frame: 11 weeks

  7. EQ-5D-5L

    EQ-5D-5L questionnaire from Baseline to EoT and end of follow-up

    Time frame: 11 weeks

  8. Quality of sleep

    Quality of sleep questionnaire from Baseline to EoT and end of follow-up

    Time frame: 11 weeks

  9. Socioeconomic data

    Change in socioeconomic data from Screening to EoT

    Time frame: 4 weeks

Other outcomes

  1. Safety Outcome #1

    Adverse Events (AEs), Adverse Device Effects (ADEs), and Device Deficiencies (DDs) observed until EoT

    Time frame: 3 weeks

  2. Safety Outcome #2

    Serious Adverse Events (SAEs), Serious Adverse Device Effects (SADEs), and related AEs observed until end of follow-up

    Time frame: 11 weeks

07

Study locations

6 of 6 sites recruiting
  • Schmerzambulanz, Krankenhaus der Elisabethinen Graz
    Graz, 8020, Austria
    Recruiting
    • Michael Kern, Dr. · Contact
    • Michael Kern, Dr. · Principal investigator
    • Julia Kolb, Dr. · Sub investigator
  • Abteilung für Anästhesiologie und Intensivmedizin, Klinikum Klagenfurt am Wörthersee
    Klagenfurt, 9020, Austria
    Recruiting
    • Rudolf Likar, Prof. Dr. · Contact
    • Rudolf Likar, Prof. Dr. · Principal investigator
    • Stefan Neuwersch-Sommeregger, Dr. · Sub investigator
    • Markus Köstenberger, Dr. · Sub investigator
  • Krankenhaus St. Vinzenz Zams
    Zams, 6511, Austria
    Recruiting
    • Andreas Wolf, Dr. · Contact
    • Andreas Wolf, Dr. · Principal investigator
    • Christian Wolf, Dr. · Sub investigator
  • RSB Neurochirurgie AG, Salem-Spital Bern
    Bern, 3013, Switzerland
    Recruiting
    • Ralph Binggeli, Dr. · Contact
    • Ralph Binggeli, Dr. · Principal investigator
    • Bernhard Voller, Prof. Dr. · Sub investigator
  • Clinique de la Douleur, La Tour Hospital
    Meyrin, 1217, Switzerland
    Recruiting
    • Christophe Perruchoud, PD Dr. · Contact
    • Christophe Perruchoud, PD Dr. · Principal investigator
    • Blaise Rutschmann, Dr. · Sub investigator
  • Schmerzklinik Zürich AG
    Zurich, 8050, Switzerland
    Recruiting
    • Michael Hartmann, Dr. · Contact
    • Michael Hartmann, Dr. · Principal investigator
    • Tomislav Kovacevic, Dr. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Mar 2027, 46 months after the start.

Of 205 interventional studies with no phase under Myofascial Pain Syndromes, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's planned 46 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2023
First posted
May 9, 2023
StartActual
May 25, 2023
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2027
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05851326
Lead sponsor
Sobet AG
Collaborators
Klinikum Klagenfurt am Wörthersee, Krankenhaus der Elisabethinen Graz, Krankenhaus St. Vinzenz Zams, La Tour Hospital, Schmerzklinik Zürich, Salem-Spital Bern
Responsible party
Sponsor
First posted
May 9, 2023
Start date
May 25, 2023
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Apr 23, 2026

Study contacts

Lidia Anguiano, Dr.
Contact
lidia.anguiano@alirahealth.com
+49 1511 0177825
Rudolf Likar, Prof. Dr.
principal investigator · Klinikum Klagenfurt am Wörthersee

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion